Pancreatic cancer - PubMed (original) (raw)
Review
. 1994 Sep-Oct;44(5):304-18.
doi: 10.3322/canjclin.44.5.304.
Affiliations
- PMID: 7521272
- DOI: 10.3322/canjclin.44.5.304
Free article
Review
Pancreatic cancer
M M Murr et al. CA Cancer J Clin. 1994 Sep-Oct.
Free article
Abstract
Pancreatic cancer is a devastating disease for the patient and presents challenging diagnostic and management problems for the physician. A range of serologic and radiologic studies are available for evaluation and staging of this disease. However, invasive studies, including laparotomy, are often necessary to establish the diagnosis and resectability. Despite advances in diagnostic technology that have shortened the interval between onset of symptoms and definitive treatment, no appreciable impact on survival has been demonstrated conclusively. Operative resection offers the only hope for cure, but fewer than 15 percent of patients have resectable disease at the time of diagnosis. Palliative therapy, whether operative or nonoperative, can be performed with low morbidity and provides significant relief of symptoms. Combined-modality treatment with chemotherapy and radiation therapy prolongs survival following curative resection.
Similar articles
- Current management of pancreatic carcinoma.
Lillemoe KD. Lillemoe KD. Ann Surg. 1995 Feb;221(2):133-48. doi: 10.1097/00000658-199502000-00003. Ann Surg. 1995. PMID: 7531966 Free PMC article. Review. - Pancreatic adenocarcinoma.
Bond-Smith G, Banga N, Hammond TM, Imber CJ. Bond-Smith G, et al. BMJ. 2012 May 16;344:e2476. doi: 10.1136/bmj.e2476. BMJ. 2012. PMID: 22592847 Review. No abstract available. - Pancreatic adenocarcinoma.
Eskander MF, Bliss LA, Tseng JF. Eskander MF, et al. Curr Probl Surg. 2016 Mar;53(3):107-54. doi: 10.1067/j.cpsurg.2016.01.001. Epub 2016 Jan 11. Curr Probl Surg. 2016. PMID: 26923296 Review. No abstract available. - Pancreatic cancer.
Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE, Iacobuzio-Donahue CA, Maitra A, Goggins M, Canto MI, Abrams RA, Laheru D, Jaffee EM, Hidalgo M, Yeo CJ. Yeo TP, et al. Curr Probl Cancer. 2002 Jul-Aug;26(4):176-275. doi: 10.1067/mcn.2002.129579. Curr Probl Cancer. 2002. PMID: 12399802 Review. No abstract available.
Cited by
- A comprehensive study of Sansalvamide A derivatives: The structure-activity relationships of 78 derivatives in two pancreatic cancer cell lines.
Pan PS, Vasko RC, Lapera SA, Johnson VA, Sellers RP, Lin CC, Pan CM, Davis MR, Ardi VC, McAlpine SR. Pan PS, et al. Bioorg Med Chem. 2009 Aug 15;17(16):5806-25. doi: 10.1016/j.bmc.2009.07.017. Epub 2009 Jul 15. Bioorg Med Chem. 2009. PMID: 19643615 Free PMC article. - Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: a cyclic tetrapeptide scaffold.
Singh EK, Ravula S, Pan CM, Pan PS, Vasko RC, Lapera SA, Weerasinghe SV, Pflum MK, McAlpine SR. Singh EK, et al. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2549-54. doi: 10.1016/j.bmcl.2008.03.047. Epub 2008 Mar 20. Bioorg Med Chem Lett. 2008. PMID: 18381239 Free PMC article. - Matrix metalloproteinase inhibition improves survival in an orthotopic model of human pancreatic cancer.
Zervox EE, Franz MG, Salhab KF, Shafii AE, Menendez J, Gower WR, Rosemurgy AS. Zervox EE, et al. J Gastrointest Surg. 2000 Nov-Dec;4(6):614-9. doi: 10.1016/s1091-255x(00)80111-0. J Gastrointest Surg. 2000. PMID: 11307097 - Identification and characterization of endonuclein binding proteins: evidence of modulatory effects on signal transduction and chaperone activity.
Ludvigsen M, Østergaard M, Vorum H, Jacobsen C, Honoré B. Ludvigsen M, et al. BMC Biochem. 2009 Dec 22;10:34. doi: 10.1186/1471-2091-10-34. BMC Biochem. 2009. PMID: 20028516 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical